Patents by Inventor Gabriela Mustata Wilson

Gabriela Mustata Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule analogs of the nemo binding peptide
    Patent number: 10758522
    Abstract: The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-?B essential modulator (“NEMO”) with I?B kinase-? (IKK-?) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-?B essential modulator (“NEMO”) with I?B kinase-? (IKK-?) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: September 1, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Paul Robbins, Laura Niedernhofer, Theodore Kamenecka, Gabriela Mustata Wilson
  • Small Molecule Analogs of the Nemo Binding Peptide
    Publication number: 20180169078
    Abstract: The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-?B essential modulator (“NEMO”) with I?B kinase-? (IKK-?) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-?B essential modulator (“NEMO”) with I?B kinase-? (IKK-?) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.
    Type: Application
    Filed: May 25, 2016
    Publication date: June 21, 2018
    Inventors: Paul Robbins, Laura Niedernhofer, Theodore Kamenecka, Gabriela Mustata Wilson